Bendamustine Injection

Bendamustine Injection Specification

Salt Composition
Bendamustine Hydrochloride

Indication
Chronic lymphocytic leukemia, Non-Hodgkin lymphoma

Dosage Form
Injection

Feature
Lyophilized powder or solution for injection; sterile and pyrogen-free

Ingredients
Bendamustine HCl, excipients

Application
Intravenous use (IV only)

Ph Level
Neutral to slightly acidic (range 6.0-7.5)

Physical Color/Texture
Clear, colorless to pale yellow solution

Fermentation Smell
Odorless

Storage Instructions
Store below 25C; protect from light

Shelf Life
24 months

Precautions
Monitor blood counts and liver function

Reconstitution
Reconstitute with sterile water for injection

Dilution Instructions
Dilute further with 0.9% sodium chloride before administration

Marketed By
As per packaging or regulatory source

Strength
100 mg per vial

Packaging
Single-use glass vial

Preservative
Does not contain preservative

Contraindications
Hypersensitivity to Bendamustine or any excipients

Administration Route
Intravenous infusion only

Regulatory Status
Prescription medicine (Rx only)

About Bendamustine Injection

Bendamustine Injection:-

Bendit (Generic Treanda) is a rationally designed purine analog and alkylator hybrid. It damages the DNA in cancer cells, which leads to the normal path of cell death (apoptosis). It also stops cancer cells from dividing to create new cancer cells.

Bendit (Generic Treanda) is specifically indicated for: 1) the treatment of chronic lymphocytic leukemia where efficacy relative to first line therapies other than chlorambucil has not been established, and 2) indolent B-cell non-Hodgkins lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Bendit (Generic Treanda) is supplied as a powder in a 100 mg vial to be reconstituted with sterile water for intravenous administration.

The recommended initial dose of the drug for the treatment of non-Hodgkin's lymphoma is 120 mg/m2 administered intravenously over 60 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles. Bendit (Generic Treanda) administration should be delayed in the event of a Grade 4 hematologic toxicity or clinically significant > Grade 2 non-hematologic toxicity.
Dose modifications for hematologic toxicity: reduce the dose to 90 mg/m2 on Days 1 and 2 of each cycle. If Grade 4 toxicity recurs, reduce the dose to 60 mg/m2 on Days 1 and 2 of each cycle.
Dose modifications for non-hematologic toxicity: reduce the dose to 90 mg/m2 on Days 1 and 2 of each cycle. If Grade 3 or greater toxicity recurs, reduce the dose to 60 mg/m2 on Days 1 and 2 of each cycle.

The recommended initial dose of the drug for the treatment of chronic lymphocytic leukemia is 100 mg/m2 administered intravenously over 30 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles. Bendit (Generic Treanda) administration should be delayed in the event of Grade 4 hematologic toxicity or clinically significant >Grade 2 non-hematologic toxicity.
Dose modifications for hematologic toxicity: reduce the dose to 50 mg/m2 on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 25 mg/m2 on Days 1 and 2 of each cycle.

Indications and Dosage

Bendamustine Injection is designed for use in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma. The specific dosage and administration schedule should be determined by a healthcare professional based on the patients clinical condition and established guidelines. Always adhere strictly to prescribed instructions.

Preparation and Administration

Before administration, the lyophilized powder must be reconstituted with sterile water for injection, then further diluted with 0.9% sodium chloride solution. Administration is by intravenous infusion only. The preparation must be handled under aseptic conditions and used immediately post-reconstitution to ensure sterility, as the vial does not contain preservatives.

Safety and Monitoring

This medication should only be used under the supervision of qualified medical personnel. Blood counts and liver function must be closely monitored throughout the treatment due to potential myelosuppression and hepatic effects. Patients with known hypersensitivity to Bendamustine or its excipients must not use this product.

FAQs of Bendamustine Injection:

Q: How should Bendamustine Injection be prepared for use?

A: Reconstitute each 100 mg vial of Bendamustine with sterile water for injection as detailed in the product insert. After reconstitution, the solution needs to be further diluted with 0.9% sodium chloride before administration by intravenous infusion. This preparation ensures appropriate concentration and safe delivery.

Q: What are the main medical conditions treated with Bendamustine Injection?

A: Bendamustine Injection is primarily indicated for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. It is used under medical supervision and as part of a carefully monitored chemotherapy regimen.

Q: When should Bendamustine Injection be administered, and who decides the dosing schedule?

A: The timing and frequency of Bendamustine Injection administration are determined by the treating physician based on the patients condition and specific therapeutic guidelines. All dosing must follow the oncologists protocol to maximize treatment efficacy and minimize risks.

Q: Where should Bendamustine Injection be stored prior to use?

A: Store Bendamustine Injection below 25C and protect it from light. Proper storage helps maintain the medications potency and ensures safety up to its 24-month shelf life.

Q: What precautions are necessary during Bendamustine Injection therapy?

A: While on Bendamustine therapy, patients should undergo regular monitoring of blood counts and liver function to detect potential adverse effects early. Due to the absence of preservatives, any unused reconstituted solution must not be stored and should be discarded immediately after use.

Q: What are the benefits of using Bendamustine Injection in cancer therapy?

A: Bendamustine Injection offers targeted chemotherapy for blood cancers like chronic lymphocytic leukemia and non-Hodgkin lymphoma, aiding in the reduction of tumor cells and potentially improving disease outcomes when used as directed by healthcare professionals.

Get Latest Price